COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Nonfunctional Pancreatic NET and PET Imaging

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02621541
Recruitment Status : Unknown
Verified January 2016 by Turku University Hospital.
Recruitment status was:  Recruiting
First Posted : December 3, 2015
Last Update Posted : January 6, 2016
Helsinki University Central Hospital
Information provided by (Responsible Party):
Turku University Hospital

Brief Summary:

Predicting aggressive behavior in the group of nonfunctional pancreatic neuroendocrine tumors (NF P-NET) remains a difficult problem in clinical practice. At present, the treatment planning in P-NET is significantly restricted by the limited results of conventional imaging. In addition, increasing use of multidetector computed tomography (MDCT) and magnetic resonance imaging (MRI) is increasing the number of NF P-NETs detected. Somatostatin receptor scintigraphy (SRS) combined with anatomical imaging are the conventional modalities in imaging of P-NET, but by these methods the diagnostic accuracy still remains compromised. Furthermore, recently encouraging results have been obtained in P-NET using 68Ga-labelled somatostatin analog, DOTA-1-NaI3-octreotide (68Ga-DOTANOC) positron emission tomography-computed tomography (PET-CT).

The aim of the current project is to evaluate the possibility to enhance the diagnostic accuracy by using dual trace functional imaging 18F-labelled fluorodeoxyglucose (18F-FDG) and 68Ga-DOTANOC PET-CT imaging in patients with NF P-NET. The study consists of 20 patients with NF P-NET. The patients enrolled in the study will be imaged 68Ga-DOTANOC and 18F-FDG PET-CT followed by surgery or follow-up with endoscopic ultrasonography (EUS) biopsies. The data will be collected between autumn 2015 and spring 2018.

Condition or disease Intervention/treatment Phase
Diagnosis Device: PET/CT Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Dual Tracer Functional Imaging of Nonfunctional Pancreatic Neuroendocrine Tumors Using 68Ga-DOTA-NOC and 18F-FDG PET/CT
Study Start Date : December 2015
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : February 2019

Arm Intervention/treatment
Experimental: Preoperative diagnosis
Preoperative diagnosis
Device: PET/CT

Primary Outcome Measures :
  1. The SUV of 68Ga-DOTANOC and 18F-FDG PET-CT predict the malignant potential of P-NETs [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • suspicion of nonfunctional P-NET on primary CT (i.e hypervascularity) or MRI
  • signed informed consent

Exclusion Criteria:

  • vulnerable study subjects such as described in Finnish law concerning clinical studies (disabled, children, pregnant or breast-feeding women, prisoners) will not be included.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02621541

Layout table for location contacts
Contact: Saila Kauhanen +358503017010

Layout table for location information
HUS Vatsakeskus Recruiting
Helsinki, Finland
Contact: Hanna Seppänen, MD, PhD         
Turku Division of Digestive Surgery and Urology Recruiting
Turku, Finland
Contact: Saila Kauhanen, MD, PhD    +358 503017010      
Sponsors and Collaborators
Turku University Hospital
Helsinki University Central Hospital
Layout table for investigator information
Principal Investigator: Saila Kauhanen, MD, PhD Turku University Hospital
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Turku University Hospital Identifier: NCT02621541    
Other Study ID Numbers: P-NETPET
First Posted: December 3, 2015    Key Record Dates
Last Update Posted: January 6, 2016
Last Verified: January 2016
Keywords provided by Turku University Hospital:
neuroendocrine tumor
positron emission tomography
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue